Patricia Walker

Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study

Naga Chalasani, Herbert L. Bonkovsky, Robert J. Fontana et al. · Gastroenterology · 2015 · 872 citations · Full text

Dilin Prospective Study, Hepatology, Medicine +10

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak et al. · The Lancet · 2020 · 583 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Oncology +8

Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial

Eitan Kerem, Michael W. Konstan, K. De Boeck et al. · The Lancet Respiratory Medicine · 2014 · 333 citations · Full text

Allergy, Placebo-controlled Phase 3, Clinical Trials +3

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

Constantine S. Tam, Jennifer R. Brown, Brad S. Kahl et al. · The Lancet Oncology · 2022 · 256 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Zanubrutinib Versus Bendamustine +10

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

Nicole Mayer-Hamblett, Félix Ratjen, Renee Russell et al. · The Lancet Respiratory Medicine · 2022 · 116 citations · Full text

Medicine, Hypertonic Saline, Dornase Alfa +1